Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage

RMD Open

Volumn 2, Issue 1, 2016, Pages

  Gallo, G ^a   Brock, F ^b   Kerkmann, U ^a   Kola, B ^a   Huizinga, T W J ^c  

^a PFIZER INC   (United States)

^b Quanticate Ltd   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988442753     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2015-000186     Document Type: Article

References (24)

1. Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010;62:674-82.
2. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a Combination Of Methotrexate and Etanercept in Active, Early, Moderate to Severe Rheumatoid Arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
3. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
4. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
5. van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83.
6. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.
7. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
8. European Medicines Agency. Enbrel: summary of product characteristics. Secondary Enbrel: summary of product characteristics. 2015. http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000262/ WC500027361.pdf (accessed 2 Mar 2015).
9. Cannon M. Methotrexate (Rheumatrex, Trexall). Secondary Methotrexate (Rheumatrex, Trexall). 2012. http://www.rheumatology. org/I-Am-A/Patient-Caregiver/Treatments/Methotrexate-Rheumatrex-Trexall (accessed 12 Apr 2016).
10. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100-4.
11. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol 2013;31(4 Suppl 78):S4-8.
12. Deighton C, O'Mahony R, Tosh J, et al. Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009;338:b702.
13. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biological agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39.
14. Burmester GR, Kivitz AJ, Kupper H, et al. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. Ann Rheum Dis 2015;74:1037-44.
15. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.
16. Furst DE, Koehnke R, Burmeister LF, et al. Increasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritis. J Rheumatol 1989;16:313-20.
17. Mielants H, Veys EM, Van der Straeten C, et al. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol 1991;18:978-83.
18. Yamanaka H, Inoue E, Tanaka E, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol 2007;17: 98-105.
19. Abbott Laboratories. Package Insert HUMIRA (adalimumab). Secondary Package Insert HUMIRA (adalimumab). 2003. http:// www.accessdata.fda.gov/drugsatfda-docs/label/2002/ adalabb123102LB.htm (accessed 1 Jul 2014).
20. Zhou H, Mayer PR, Wajdula J, et al. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004;44:1235-43.
21. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086-93.
22. Pope JE, Haraoui B, Thorne JC, et al. The Canadian Methotrexate and Etanercept Outcome study: a randomised trial of discontinuing versus continuing methotrexate after 6 months of etanercept and methotrexate therapy in rheumatoid arthritis. Ann Rheum Dis 2014;73:2144-51.
23. Emery P, Jones H, Marshall L, et al. Continuation of etanercept monotherapy after achievement of remission with etanercept and methotrexate combination therapy: subanalysis from the COMET study. Ann Rheum Dis 2015;74(Supp 2):468.
24. Fleischmann R, Koenig AS, Pedersen R, et al. Treatment outcomes based on methotrexate dose range in patients with rheumatoid arthritis receiving etanercept+methotrexate versus methotrexate alone [Abstract]. Arthitis Rheum 2011;63:S178.